SLAMF7-directed Immunostimulatory Antibody [EPC]

3388 reported adverse events

Drugs of this class: ELOTUZUMAB

These side effects are most commonly reported by patients taking drugs of the SLAMF7-directed Immunostimulatory Antibody [EPC] class:

# Side effect Count
0 PLASMA CELL MYELOMA 284
1 PNEUMONIA 235
2 DEATH 214
3 MALIGNANT NEOPLASM PROGRESSION 189
4 PYREXIA 177
5 DIARRHOEA 144
6 FATIGUE 141
7 PLATELET COUNT DECREASED 105
8 SEPSIS 105
9 ANAEMIA 103
See all common reactions for SLAMF7-directed Immunostimulatory Antibody [EPC]

Drugs of the SLAMF7-directed Immunostimulatory Antibody [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 PARAINFLUENZAE VIRAL LARYNGOTRACHEOBRONCHITIS 2 0.6667
1 HUMAN METAPNEUMOVIRUS TEST 3 0.6000
2 ANTIVIRAL PROPHYLAXIS 1 0.2000
3 ANORECTAL HUMAN PAPILLOMA VIRUS INFECTION 2 0.1111
4 BLADDER TRANSITIONAL CELL CARCINOMA STAGE 0 2 0.0952
5 RESPIROVIRUS TEST POSITIVE 4 0.0930
6 BLOOD IMMUNOGLOBULIN A ABNORMAL 1 0.0556
7 ENCEPHALITIS MENINGOCOCCAL 1 0.0526
8 DEDIFFERENTIATED LIPOSARCOMA 1 0.0435
9 COLON CANCER STAGE 0 1 0.0435
See all enriched reactions for SLAMF7-directed Immunostimulatory Antibody [EPC]